2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
Original-Research: Ikonisys SA - von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Ikonisys SA
Unternehmen: Ikonisys SA
ISIN: FR00140048X2
Anlass der Studie: Update Report
Empfehlung: Buy
seit: 06.02.2024
Kursziel: EUR 6,30 (bisher: EUR 4,50)
Kursziel auf Sicht von: 36 Monate
Letzte Ratingänderung: -
Analyst: Peter Thilo Hasler, CEFA
Creating a leading player in cancer diagnostics
Only weeks after Ikonisys entered a strategic partnership with Biocare
Medical, the company made the next strategic step in business development
by announcing the takeover of Hospitex, an Italian-based cytology company
specialising in oncological diagnostics. According to the company, Hospitex
has developed a unique ecosystem around a technology called Nephelometric
Smart Technology (NST). Central to the ecosystem is CYTOfast Plus, which is
claimed to be the most advanced processing solution to produce filter-less,
standardized, single-layer liquid based cytology (LBC) diagnostic slides.
While competitor technologies were originally designed only for the
so-called Pap test, a screening test for cervical cancer, the patent
protected NST is the only certified technology for the entire cytology
universe and for all target organs, according to the company. We believe
that Hospitex could prove a perfect fit to extend Ikonisys’ value chain and
should significantly support the company's growth and profitability in the
years ahead. After adjusting our financial model to the acquisition and the
new number of shares, the intrinsic value derived from our three-stage DCF
entity model increases to EUR 6.30 from EUR 4.50 per share (base case
scenario). We reiterate our Buy rating.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/28825.pdf
Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553
peter-thilo.hasler@sphene-capital.de
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
